Table 1. . Phase III combination trials for the treatment of metastatic melanoma. Checkpoint inhibition and immunotherapy: anti-CTLA-4 and anti-PD-1 combination in the Checkmate 067 study.

Treatment	Number of patients	Response rates (%)	mPFS (months)	Grade 3–4 AEs (%)
Nivolumab + ipilimumab	314	57	11.5	55.0
Nivolumab	316	44	6.9	16.3
Ipilimumab	315	19	2.9	27.3

AE: Adverse event; mPFS: Median progresson-free survival.

Data taken from [2,30–33].